TWEAK and Fn14: new molecular targets for cancer therapy?

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a cytokine in the TNF superfamily.
• TWEAK exists as membrane-anchored and soluble forms, interacting with the fibroblast growth factor-inducible 14 (Fn14) receptor.
• The TWEAK-Fn14 axis influences critical cellular processes.

Purpose of the Study:

• To review recent studies on the role of TWEAK and Fn14 in human tumorigenesis.
• To explore the implications of TWEAK-Fn14 signaling in cancer.
• To highlight potential therapeutic targets in cancer treatment.

Main Methods:

• Review of recent scientific literature.
• Analysis of studies investigating TWEAK and Fn14 signaling pathways.
• Examination of the role of nuclear factor-kappaB activation.

Main Results:

• TWEAK binding to Fn14 activates the nuclear factor-kappaB (NF-κB) signaling pathway.
• NF-κB is implicated in immune responses, inflammation, oncogenesis, and cancer therapy resistance.
• Evidence suggests TWEAK and Fn14 are potential regulators of human tumor development.

Conclusions:

• The TWEAK-Fn14 pathway is a significant factor in human tumorigenesis.
• Targeting the TWEAK-Fn14 axis may offer novel strategies for cancer therapy.
• Further research is warranted to fully elucidate the role of TWEAK and Fn14 in cancer.